inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis . The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhA was identified as the target of activated INH by an M. smegmatis missense mutation that conferred co-resistance to both INH and Ethionamide (ETH) (129).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [129]
Citations
Cites
Introduction to Protein Structure
Branden, C. I., & Tooze, J. (2012) · Garland Science eBooks · doi:10.1201/9781136969898 · Cited by 2,382
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
Self-citationThe Emergence of Drug-Resistant Tuberculosis in New York City
Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M., & Dooley, S. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280801 · Cited by 939
Tuberculosis in developing countries: burden, intervention and cost.
Murray, C. J. L., Styblo, K., & Rouillon, A. (1990) · PubMed · Cited by 571
[25] Genetic systems for mycobacteria
Jacobs, W. R., Kalpana, G. V., Cirillo, J. D., Pascopella, L., Snapper, S. B., Udani, R. A., Jones, W., Barletta, R. G., & Bloom, B. R. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)04027-l · Cited by 433
Self-citationSnider, D. E., & Roper, W. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261011 · Cited by 382
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Takayama, K., Wang, L., & David, H. L. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.1.29 · Cited by 292
Research works printed but not linked: 8
- BEGGS, W.H., AM REV RESPIR DIS 102: 94 (1969).
- GOPINATHAN, K.P., SPECIFICITY OF ISONIAZID ACTION AGAINST MYCOBACTERIA AND A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF DRUG-RESISTANCE, CURRENT SCIENCE 50: 216 (1981).
- GRUMBACH, F, REVUE DE TUBERCULOSE ET DE PNEUMOLOGIE 25: 1365 (1961).
- MIDDLEBROOK, G, AMERICAN REVIEW OF TUBERCULOSIS 65: 765 (1952).
- MURRAY, C. J. L., BULLETIN OF THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE 65: 6 (1990).
- Murray, C., Disease Control Priorities in Developing Countries: 233 (1993).
- OFFE, H.A., ZEITSCHRIFT FUR NATURFORSCHUNG 76: 462 (1952).
- PANSY, F, INVITRO STUDIES ON ISONICOTINIC ACID HYDRAZIDE, AMERICAN REVIEW OF TUBERCULOSIS 65: 761 (1952).
Cited by
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
“Several different components of FAS II may be targets for the important tuberculosis drug isoniazid, including the enoyl-ACP reductase Inh”
BackgroundPlatforms for antibiotic discovery
Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,445
Mycobacterium tuberculosis Pathogenesis and Molecular Determinants of Virulence
Smith, I. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.3.463-496.2003 · Cited by 1,154
“The fact that M. tuberculosis in a chronically infected mouse model is susceptible to isoniazid (INH) (238), a drug that is effective only against growing M. tuberculosis (308), provides evidence for the latter explanation, i.e., balanced growth and death.”
BackgroundInfluentialMolecular genetic basis of antimicrobial agent resistance inMycobacterium tuberculosis: 1998 update
Ramaswamy, S., & Musser, J. M. (1998) · Tubercle and Lung Disease · doi:10.1054/tuld.1998.0002 · Cited by 1,089
“coli, an enzyme involved in fatty acid biosynthesis.(96) The mycobacterial”
BackgroundResultWHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,100
THE STRUCTURAL BIOLOGY OF TYPE II FATTY ACID BIOSYNTHESIS
White, S. W., Zheng, J., Zhang, Y.-M., & Rock, C. O. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133524 · Cited by 832
The Envelope Layers of Mycobacteria with Reference to their Pathogenicity
Daffé, M., & Draper, P. (1997) · Advances in Microbial Physiology · doi:10.1016/s0065-2911(08)60016-8 · Cited by 730
Scorpio, A., & Zhang, Y. (1996) · Nature Medicine · doi:10.1038/nm0696-662 · Cited by 726
Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosis
Rozwarski, D. A., Grant, G. A., Barton, D. H. R., Jacobs, W. R., & Sacchettini, J. C. (1998) · Science · doi:10.1126/science.279.5347.98 · Cited by 682
Self-citationPathway to Synthesis and Processing of Mycolic Acids in Mycobacterium tuberculosis
Takayama, K., Wang, C., & Besra, G. S. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.81-101.2005 · Cited by 660
“Jacobs and associates and others showed that the target of inhibition of mycolic acid synthesis by isoniazid is 2-trans-enoyl-ACP reductase (InhA) of the FAS-II elongation pathway (10, 59, 111).”
BackgroundMycolic Acids: Structures, Biosynthesis, and Beyond
Marrakchi, H., Lanéelle, M.-A., & Daffé, M. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.11.011 · Cited by 623
Antimicrobial agent resistance in mycobacteria: molecular genetic insights
Musser, J. M. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.496 · Cited by 621
“Ethionamide As noted above, ETH (2-ethylpyridine-4-carbonic acid thioamide) is a derivative of isonicotinic acid with potent activity against M. tuberculosis and other mycobacteria (38, 60, 90, 130).”
BackgroundMethodInfluentialBest drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
Caminero, J. A., Sotgiu, G., Zumla, A., & Migliori, G. B. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70139-0 · Cited by 574
Mycolic acids: structure, biosynthesis and physiological functions
Barry, C. E., Lee, R. E., Mdluli, K., Sampson, A. E., Schroeder, B. G., Slayden, R. A., & Yuan, Y. (1998) · Progress in Lipid Research · doi:10.1016/s0163-7827(98)00008-3 · Cited by 565
Wilson, M., DeRisi, J., Kristensen, H.-H., Imboden, P., Rane, S., Brown, P. O., & Schoolnik, G. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12833 · Cited by 547
Brown-Elliott, B. A., Nash, K. A., & Wallace, R. J. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05030-11 · Cited by 541
“More recently, the primary target of activated isoniazid was identified as one of the fatty acid synthesis II (FAS II) enzymes, enoyl-acyl carrier protein (ACP) reductase, or InhA (20, 197, 203).”
BackgroundMechanism of Triclosan Inhibition of Bacterial Fatty Acid Synthesis
Heath, R. J., Rubin, J. R., Holland, D. R., Zhang, E., Snow, M. E., & Rock, C. O. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.11110 · Cited by 542
Almeida Da Silva, P. E., & Palomino, J. C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr173 · Cited by 532
Antituberculosis drugs: Ten years of research
Janin, Y. L. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.01.030 · Cited by 485
Bacterial Fatty Acid Biosynthesis: Targets for Antibacterial Drug Discovery
Campbell, J. W., & Cronan, J. E. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.305 · Cited by 479
The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol
Telenti, A., Philipp, W. J., Sreevatsan, S., Bernasconi, C., Stockbauer, K. E., Wieles, B., Musser, J. M., & Jacobs, W. R. (1997) · Nature Medicine · doi:10.1038/nm0597-567 · Cited by 472
Self-citationEvolution and transmission of drug-resistant tuberculosis in a Russian population
Casali, N., Nikolayevskyy, V., Balabanova, Y., Harris, S. R., Ignatyeva, O., Kontsevaya, I., Corander, J., Bryant, J., Parkhill, J., Nejentsev, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2878 · Cited by 473
Lambert, P. A. (2002) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.92.5s1.7.x · Cited by 450
“The related antimycobacterial agent, ethionamide, probably acts in a similar manner to isoniazid since mutation in the inhA gene results in resistance to both agents (Banerjee et al. 1994).”
BackgroundAntimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives
Gygli, S. M., Borrell, S., Trauner, A., & Gagneux, S. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux011 · Cited by 457
Consequences of genomic diversity in Mycobacterium tuberculosis
Coscolla, M., & Gagneux, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.09.012 · Cited by 451
“For example, several intergenic SNPs in the promoter of the inhA gene, increase the transcription level of inhA, thereby conferring resistance to isoniazid and ethionomide [101,102].”
BackgroundDrug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
“Mutations in inhA not only cause resistance to isoniazid but also to the structurally related drug ethionamide, which shares the same target [30,31].”
BackgroundCrystal Structure and Function of the Isoniazid Target of Mycobacterium tuberculosis
Dessen, A., Quémard, A., Blanchard, J. S., Jacobs, W. R., & Sacchettini, J. C. (1995) · Science · doi:10.1126/science.7886450 · Cited by 430
Self-citationTHE MAGIC BULLETS AND TUBERCULOSIS DRUG TARGETS
Zhang, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100120 · Cited by 432
“ETH/PTH ETH, structurally related to INH (Figure 1), is also a prodrug that is activated by the enzyme EtaA (a monooxygenase, also called EthA) (58, 59) and inhibits the same target InhA as INH (50) of the mycolic acid synthesis pathway.”
BackgroundMechanisms of action of isoniazid
Timmins, G. S., & Deretic, V. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05467.x · Cited by 421
“InhA is an enoyl acyl carrier protein reductase (Banerjee et al., 1994; Dessen et al., 1995) involved in the synthesis of mycolic acids, unique and important mycobacterial cell wall lipids, and so its inhibition is in accord with the unique sensitivity of mycobacteria to INH.”
BackgroundRussell, A. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00833-8 · Cited by 419
Bacterial Growth and Cell Division: a Mycobacterial Perspective
Hett, E. C., & Rubin, E. J. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00028-07 · Cited by 408
Inhibition of a Mycobacterium tuberculosis β-Ketoacyl ACP Synthase by Isoniazid
Mdluli, K., Slayden, R. A., Zhu, Y., Ramaswamy, S., Pan, X., Mead, D., Crane, D. D., Musser, J. M., & Barry, C. E. (1998) · Science · doi:10.1126/science.280.5369.1607 · Cited by 398
Alvin, A., Miller, K. I., & Neilan, B. A. (2014) · Microbiological Research · doi:10.1016/j.micres.2013.12.009 · Cited by 373
Campbell, P. J., Morlock, G. P., Sikes, R. D., Dalton, T. L., Metchock, B., Starks, A. M., Hooks, D. P., Cowan, L. S., Plikaytis, B. B., & Posey, J. E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01550-10 · Cited by 379
“Nineteen of the INH-resistant isolates were wild type at both these locations and also in the region of the inhA structural gene where resistance-associated mutations have been reported (data not shown) (3, 4).”
Mechanisms of Drug Resistance in Mycobacterium tuberculosis
Heym, B., Philipp, W., & Cole, S. T. (1996) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-80166-2_3 · Cited by 379
Enzymic Characterization of the Target for Isoniazid in Mycobacterium tuberculosis
Quemard, A., Sacchettini, J. C., Dessen, A., Vilcheze, C., Bittman, R., Jacobs, W. R., & Blanchard, J. S. (1995) · Biochemistry · doi:10.1021/bi00026a004 · Cited by 373
Self-citationDiscovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties
Wang, J., Kodali, S., Lee, S. H., Galgoci, A., Painter, R., Dorso, K., Racine, F., Motyl, M., Hernandez, L., Tinney, E., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700746104 · Cited by 381
Hazbón, M. H., Brimacombe, M., Bobadilla del Valle, M., Cavatore, M., Guerrero, M. I., Varma-Basil, M., Billman-Jacobe, H., Lavender, C., Fyfe, J., García-García, L., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00112-06 · Cited by 374
“Laboratory studies have suggested that expression of the inhA gene may be tightly regulated, as inhA cannot be overexpressed on a multicopy plasmid using its native promoter (5).”
BackgroundTackling Threats and Future Problems of Multidrug-Resistant Bacteria
Medina, E., & Pieper, D. H. (2016) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2016_492 · Cited by 356
Heath, R. J., & Rock, C. O. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.44.26538 · Cited by 368
Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis
Coll, F., Phelan, J., Hill-Cawthorne, G. A., Nair, M. B., Mallard, K., Ali, S., Abdallah, A. M., Alghamdi, S., Alsomali, M., Ahmed, A. O., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0029-0 · Cited by 375
Multidrug-Resistant Mycobacterium tuberculosis: Molecular Perspectives
Rattan, A., Kalia, A., & Ahmad, N. (1998) · Emerging Infectious Diseases · doi:10.3201/eid0402.980207 · Cited by 355
“Efforts to determine the factors involved in resistance to INH led to the discovery of the inhA locus, which was proposed as the primary target for coresistance to INH and ethionamide (54).”
BackgroundLipid biosynthesis as a target for antibacterial agents
Heath, R. J., White, S. W., & Rock, C. O. (2001) · Progress in Lipid Research · doi:10.1016/s0163-7827(01)00012-1 · Cited by 344
Dookie, N., Rambaran, S., Padayatchi, N., Mahomed, S., & Naidoo, K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx506 · Cited by 346
Broad Spectrum Antimicrobial Biocides Target the FabI Component of Fatty Acid Synthesis
Heath, R. J., Yu, Y.-T., Shapiro, M. A., Olson, E., & Rock, C. O. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30316 · Cited by 337
Ramaswamy, S. V., Reich, R., Dou, S.-J., Jasperse, L., Pan, X., Wanger, A., Quitugua, T., & Graviss, E. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1241-1250.2003 · Cited by 336
“Also, the mutations identified in the structural part of inhA results in INH resistance due to a reduced binding affinity of the INHNAD adduct for enoyl reductase (4, 7, 29).”
The Mechanism of Isoniazid Killing: Clarity Through the Scope of Genetics
Vilchèze, C., & Jacobs, Jr. (2007) · Annual Review of Microbiology · doi:10.1146/annurev.micro.61.111606.122346 · Cited by 335
Self-citationEthionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis
DeBarber, A. E., Mdluli, K., Bosman, M., Bekker, L.-G., & Barry, C. E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9677 · Cited by 338
Rawat, R., Whitty, A., & Tonge, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235848100 · Cited by 330
Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis
Rock, C. O., & Cronan, J. E. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(96)00056-2 · Cited by 332
Heym, B., Alzari, P. M., Honore, N., & Cole, S. T. (1995) · Molecular Microbiology · doi:10.1111/j.1365-2958.1995.tb02238.x · Cited by 330
Seifert, M., Catanzaro, D., Catanzaro, A., & Rodwell, T. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119628 · Cited by 326
Telenti, A., Honoré, N., Bernasconi, C., March, J., Ortega, A., Heym, B., Takiff, H. E., & Cole, S. T. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.3.719-723.1997 · Cited by 320
“In contrast, resistance to INH is associated with a variety of mutations affecting one or more genes such as those encoding catalase-peroxidase (katG) (28), the enoyl-acyl carrier protein reductase involved in mycolic acid biosynthesis (inhA) (1), and the recently described alkyl-hydroperoxide reductase (ahpC), which…”
BackgroundTransfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid
Vilchèze, C., Wang, F., Arai, M., Hazbón, M. H., Colangeli, R., Kremer, L., Weisbrod, T. R., Alland, D., Sacchettini, J. C., & Jacobs, W. R. (2006) · Nature Medicine · doi:10.1038/nm1466 · Cited by 319
Self-citationKinnings, S. L., Liu, N., Buchmeier, N., Tonge, P. J., Xie, L., & Bourne, P. E. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000423 · Cited by 319
“Since InhA is the primary target of the anti-tubercular drugs isoniazid [17] and ethionamide [18], entacapone and tolcapone can potentially inhibit the InhA ligand binding site directly.”
BackgroundKapur, V, Li, L. L., Iordanescu, S., Hamrick, M. R., Wanger, A., Kreiswirth, B. N., & Musser, J. M. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.4.1095-1098.1994 · Cited by 317
“tions, such as isoniazid (1, 4), streptomycin (5, 7, 18), and”
BackgroundMusser, J. M., Kapur, V., Williams, D. L., Kreiswirth, B. N., van Soolingen, D., & van Embden, J. D. A. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.1.196 · Cited by 313
“A further complicating issue has arisen due to the identification of a second genetic locus conferring both isoniazid and ethionamide resistance in the laboratory when present on a multicopy plasmid [15].”
BackgroundActivation of the Pro-drug Ethionamide Is Regulated in Mycobacteria
Baulard, A. R., Betts, J. C., Engohang-Ndong, J., Quan, S., McAdam, R. A., Brennan, P. J., Locht, C., & Besra, G. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003744200 · Cited by 311
Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis
Unissa, A. N., Subbian, S., Hanna, L. E., & Selvakumar, N. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.09.004 · Cited by 300
Mechanism of thioamide drug action against tuberculosis and leprosy
Wang, F., Langley, R., Gulten, G., Dover, L. G., Besra, G. S., Jacobs, W. R., & Sacchettini, J. C. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062100 · Cited by 303
“However, four diff erent mechanisms of coresistance to INH and ETH have been discovered: (a) overexpression of the InhA target (6, 12); (b) target modifi cation to prevent adduct binding (8); (c) activator modifi cation to prevent prodrug activation and adduct formation (20); and (d) mutations in ndh, the gene encodin…”
BackgroundSelf-citationethA , inhA , and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates
Morlock, G. P., Metchock, B., Sikes, D., Crawford, J. T., & Cooksey, R. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3799-3805.2003 · Cited by 288
“The structural similarity and existence of cross-resistant phenotypes suggested that these two drugs share a common molecular target (1).”
BackgroundInfluentialVilchèze, C., & Jacobs JR., W. R. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0014-2013 · Cited by 289
“tuberculosis: the enoyl-ACP reductase InhA (56).”
BackgroundSelf-citationRozwarski, D. A., Vilchèze, C., Sugantino, M., Bittman, R., & Sacchettini, J. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.22.15582 · Cited by 290
Vilchèze, C., Morbidoni, H. R., Weisbrod, T. R., Iwamoto, H., Kuo, M., Sacchettini, J. C., & Jacobs, W. R. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.14.4059-4067.2000 · Cited by 283
“smegmatis cells and INH-R to inhibition of cell extracts (1).”
BackgroundMethodInfluentialSelf-citationAltered NADH/NAD + Ratio Mediates Coresistance to Isoniazid and Ethionamide in Mycobacteria
Vilchèze, C., Weisbrod, T. R., Chen, B., Kremer, L., Hazbón, M. H., Wang, F., Alland, D., Sacchettini, J. C., & Jacobs, W. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.708-720.2005 · Cited by 284
“Two other antimycobacterial agents, ETH and TRC, both targeting InhA (1, 34), were also tested.”
BackgroundResultInfluentialSelf-citationRaman, K., Yeturu, K., & Chandra, N. (2008) · BMC Systems Biology · doi:10.1186/1752-0509-2-109 · Cited by 280
“Proteins such as KasA (Rv2245), KasB (Rv2246), MabA (Rv1483), RmlB (Rv3464), which have been suggested as potential targets in earlier studies, have all been eliminated at this stage, due to the presence of close homologues in the human proteome.”
BackgroundInfluentialTBResist Global Genome Consortium, Manson, A. L., Cohen, K. A., Abeel, T., Desjardins, C. A., Armstrong, D. T., Barry, C. E., Brand, J., Chapman, S. B., Cho, S.-N., et al. (2017) · Nature Genetics · doi:10.1038/ng.3767 · Cited by 280
“While inhA mutations can confer resistance to both isoniazid and ethionamide 65 , we defined genotypic ethionamide resistance as mutations in only ethA to simplify the analysis and avoid double counting.”
The Concept of an Ideal Antibiotic: Implications for Drug Design
Gajdács, M. (2019) · Molecules · doi:10.3390/molecules24050892 · Cited by 271
Zimhony, O., Cox, J. S., Welch, J. T., Vilchèze, C., & Jacobs, W. R. (2000) · Nature Medicine · doi:10.1038/79558 · Cited by 270
Self-citationTroesch, A., Nguyen, H., Miyada, C. G., Desvarenne, S., Gingeras, T. R., Kaplan, P. M., Cros, P., & Mabilat, C. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.1.49-55.1999 · Cited by 272
“For example, probe array-based mutation analysis of the catalase-peroxidase gene (katG) (31), the promoter region of the inhA and ahpC genes (1, 29), the recently described kasA protein (19) for isoniazid resistance, pyrazinamidase-nicotinamidase gene (pncA) for pyrazinamide resistance (22, 24), and the emb operon for…”
BackgroundJackson, M., Raynaud, C., Lanéelle, M., Guilhot, C., Laurent‐Winter, C., Ensergueix, D., Gicquel, B., & Daffé, M. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01310.x · Cited by 267
“Considering the importance of the cell envelope structure for bacterial survival (Banerjee et al., 1994; Belanger et al., 1996), many attempts have been made to identify the enzymes involved in the metabolism of such specific compounds which obviously represent attractive targets for the design of…”
BackgroundTargeting Tuberculosis and Malaria through Inhibition of Enoyl Reductase
Kuo, M. R., Morbidoni, H. R., Alland, D., Sneddon, S. F., Gourlie, B. B., Staveski, M. M., Leonard, M., Gregory, J. S., Janjigian, A. D., Yee, C., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211968200 · Cited by 263
Self-citationThe Mycobacterial Cell Envelope--Lipids
Jackson, M. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021105 · Cited by 269
“These features account for the specificity and therapeutic efficacy of first- and second-line TB drugs such as INH and ETH, which inhibit the biosynthesis of mycolic acids (Banerjee et al. 1994; Vilchèze and Jacobs 2007; Grzegorzewicz et al. 2012b) (Fig.”
BackgroundInhibiting Bacterial Fatty Acid Synthesis
Zhang, Y.-M., White, S. W., & Rock, C. O. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.r600004200 · Cited by 263
Heym, B., Honoré, N., Schurra, C., Cole, S. T., Heym, B., Truffot-Pernot, C., Grosset, J. H., Banerjee, A., Jacobs, W. R., & van Embden, J. D. A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91338-2 · Cited by 263
Self-citationMechanisms of Drug Resistance in Mycobacterium tuberculosis
Zhang, Y., Vilchèze, C., & Jacobs, W. R. (2004) · Tuberculosis and the Tubercle Bacillus · doi:10.1128/9781555817657.ch8 · Cited by 261
“Resistance to INH occurs more frequently than for most anti-tuberculosis drugs, at a frequency of 1 in 105–6 bacilli in vitro.47 INH-resistant clinical isolates of M. tuberculosis often lose catalase and peroxidase enzyme48 encoded by katG, especially in highlevel resistant strains (MIC > 5 μg/ml).47 Low-level resista…”
BackgroundResultInfluentialSelf-citationHe, X., Alian, A., Stroud, R., & Ortiz de Montellano, P. R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060715y · Cited by 257
Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway
Lu, H., & Tonge, P. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700156e · Cited by 254
Kremer, L., Douglas, J. D., Baulard, A. R., Morehouse, C., Guy, M. R., Alland, D., Dover, L. G., Lakey, J. H., Jacobs, W. R., Brennan, P. J., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000569200 · Cited by 256
Self-citationPhilipp, W. J., Poulet, S., Eiglmeier, K., Pascopella, L., Balasubramanian, V, Heym, B., Bergh, S., Bloom, B. R., Jacobs, W. R., & Cole, S. T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.3132 · Cited by 254
Self-citationRussell, A. D. (2002) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.92.5s1.12.x · Cited by 246
“A protein target, encoded by the inhA gene (Bannerjee et al. 1994), is involved in mycolic acid biosynthesis.”
BackgroundA Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase
Baldock, C., Rafferty, J. B., Sedelnikova, S. E., Baker, P. J., Stuitje, A. R., Slabas, A. R., Hawkes, T. R., & Rice, D. W. (1996) · Science · doi:10.1126/science.274.5295.2107 · Cited by 239
Heath, R. J., Li, J., Roland, G. E., & Rock, C. O. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.7.4654 · Cited by 240
Marrakchi, H., Lanéelle, G., & Quémard, A. (2000) · Microbiology · doi:10.1099/00221287-146-2-289 · Cited by 238
“As data presented by Banerjee et al. (1994) strongly suggest that the inhA gene is involved in the production of very-long-chain fatty acids, mycolic acids, it is reasonable to imagine that InhA is part of a fatty acid elongation system whose products represent intermediates in the biosynthesis of…”
BackgroundInfluentialBhatt, A., Molle, V., Besra, G. S., Jacobs, W. R., & Kremer, L. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05761.x · Cited by 234
“Through genetic and biochemical approaches, two genes of the FAS-II system, inhA and kasA, have been postulated to encode the primary target of INH (Banerjee et al., 1994; Mdluli et al., 1998).”
BackgroundSelf-citationSullivan, T. J., Truglio, J. J., Boyne, M. E., Novichenok, P., Zhang, X., Stratton, C. F., Li, H.-J., Kaur, T., Amin, A., Johnson, F., et al. (2006) · ACS Chemical Biology · doi:10.1021/cb0500042 · Cited by 236
The Antituberculosis Drug Ethionamide Is Activated by a Flavoprotein Monooxygenase
Vannelli, T. A., Dykman, A., & Ortiz de Montellano, P. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110751200 · Cited by 232
Machado, D., Couto, I., Perdigão, J., Rodrigues, L., Portugal, I., Baptista, P., Veigas, B., Amaral, L., & Viveiros, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034538 · Cited by 226
“Isoniazid is a prodrug that requires activation by the catalase-peroxidase enzyme (KatG) [6] and its molecular target is InhA, a NADH-dependent enoyl acyl carrier protein reductase involved in the synthesis of mycolic acids [7].”
BackgroundImpact of Bacterial Genetics on the Transmission of Isoniazid-Resistant Mycobacterium tuberculosis
Gagneux, S., Burgos, M. V., DeRiemer, K., Enciso, A., Muñoz, S., Hopewell, P. C., Small, P. M., & Pym, A. S. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020061 · Cited by 230
“is a component of FAS-II (fatty acid elongation system) that is required for mycolic acid synthesis and is a target for isoniazid [”
BackgroundMolecular Mechanisms of Multiple Drug Resistance in Clinical Isolates of Mycobacterium tuberculosis
Morris, S., Bai, G. H., Suffys, P., Portillo-Gomez, L., Fairchok, M., & Rouse, D. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.4.954 · Cited by 231
“tuberculosis [5-12].”
BackgroundDrug Resistance in Mycobacterium tuberculosis
(2006) · Current Issues in Molecular Biology · doi:10.21775/cimb.008.097 · Cited by 227
“Ethionamide (ETH) is an important drug in the treatment of MDR-TB, and is mechanistically and structurally analogous to INH.”
BackgroundInfluentialZhang, Y.-M., & Rock, C. O. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403697200 · Cited by 222
Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target
ABRAHAMS, K. A., & BESRA, G. S. (2018) · Parasitology · doi:10.1017/s0031182016002377 · Cited by 227
“…pathway (Bhatt et al. 2007), where it undergoes a round of keto-reduction, dehydration and enoyl-reduction, catalysed by: MabA, a β -ketoacyl-AcpM reductase (Marrakchi et al. 2002); HadAB/BC, a β - hydroxyacyl-AcpM hydratase (Sacco et al. 2007); InhA, an enoyl-AcpM reductase (Banerjee et al. 1994).”
InfluentialTuberculosis Drug Resistance: A Global Threat
Nachega, J. B., & Chaisson, R. E. (2003) · Clinical Infectious Diseases · doi:10.1086/344657 · Cited by 225
“Three additional genes have been identified as playing a role in isoniazid resistance: inhA and kasA code for cell wall mycolic acid biosynthetic enzymes, and mutations in these genes are found in some resistant isolates [30, 31].”
BackgroundDavies, C., Heath, R. J., White, S. W., & Rock, C. O. (2000) · Structure · doi:10.1016/s0969-2126(00)00094-0 · Cited by 222
Parris, K. D., Lin, L., Tam, A., Mathew, R., Hixon, J., Stahl, M., Fritz, C. C., Seehra, J., & Somers, W. S. (2000) · Structure · doi:10.1016/s0969-2126(00)00178-7 · Cited by 220
De Beenhouwer, H., Lhiang, Z., Jannes, G., Mijs, W., Machtelinckx, L., Rossau, R., Traore, H., & Portaels, F. (1995) · Tubercle and Lung Disease · doi:10.1016/0962-8479(95)90009-8 · Cited by 220
Li, S., Poulton, N. C., Chang, J. S., Azadian, Z. A., DeJesus, M. A., Ruecker, N., Zimmerman, M. D., Eckartt, K. A., Bosch, B., Engelhart, C. A., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01130-y · Cited by 216
MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212
La Rosa, V., Poce, G., Canseco, J. O., Buroni, S., Pasca, M. R., Biava, M., Raju, R. M., Porretta, G. C., Alfonso, S., Battilocchio, C., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05270-11 · Cited by 212
“In some cases, such as with the first-line antitubercular agent isoniazid, the identification of the cellular target proved difficult and controversial (2, 14, 19), and in others, such as with metronidazole, the target(s) remains elusive.”
BackgroundGenetic Evidence that InhA of Mycobacterium smegmatis Is a Target for Triclosan
McMurry, L. M., McDermott, P. F., & Levy, S. B. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.711 · Cited by 214
“smegmatis by a mutation (S94A, replacing serine 94 with alanine in the protein) which caused resistance to the antituberculosis drug isoniazid (3).”
Background
Metadata
- Authors
- Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461.
- AgResearch (NZ)
- AgResearch, Wallaceville Animal Research Center, Upper Hutt, New Zealand.
- Venue
- Science
- Published
- 1994-01-14
- Volume
- 263
- Issue
- 5144
- Pages
- 227-230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2075000963
- Cited by
- 1,389
- References
- 46
- Citations by year
- 2026: 24 · 2025: 32 · 2024: 31 · 2023: 43 · 2022: 49 · 2021: 39 · 2020: 45 · 2019: 52 · 2018: 52 · 2017: 62 · 2016: 45 · 2015: 54 · 2014: 69 · 2013: 39 · 2012: 57
- FWCI
- 46.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01ai030189-03)
- National Institute of Allergy and Infectious Diseases (AI 27160, UO1AI30189)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- inhA gene, isoniazid, ethionamide, Mycobacterium tuberculosis, therapeutic target, drug resistance, missense mutations, mycolic acid biosynthesis, Mycobacterium smegmatis, Mycobacterium bovis BCG, antitubercular agents
- MeSH terms
- Amino Acid Sequence, Bacterial Proteins, Base Sequence, Cloning, Molecular, Drug Resistance, Microbial, Ethionamide, Genes, Bacterial, Isoniazid, Molecular Sequence Data, Mutation, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Mycolic Acids, Oxidoreductases, Open Reading Frames, Sequence Alignment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.